3/8: A hierarchical #WinRatio was calculated for each plaque-based care patient vs each usual care patient for 4 outcomes, ranked by clinical priority:
@RobinGivhan THANK YOU for your opinion piece today in @nytimes. You put into eloquent words EXACTLY my feelings. I hope like you that one day the OLD feelings will return. But I do worry . . .
@CMichaelGibson I wish you all the best and am confident you will set the standard in ANY new endeavor you undertake--just as you did reading grayscale.
After analyzing 2,500 angios over 2 years, I'm done. Nights, weekends—all consumed. I'm tired.
My rods & cones would like a word: They miss color. I’m trading cath lab grayscale for summer’s full palette. They miss joy. They miss art.
I want summer & paint in my eyes—not contrast and cine runs. Time to swap arteries for art. 🎨☀️ #cmgsays #cmgsees color in his future
🆕🆓 #CME from @academiccme: Update on Best Practices for the Prompt and Personalized Management of Patients with #COPD Exacerbations, by William Corrao @BrighamWomens! Click on https://t.co/GUMuTZLLzP.
Salute to @GOLD_COPD! Originally presented at @EPulmonaryConf 2022.
Attending #ACEP22? Visit the @academiccme booth today, #1539, to learn about our latest offering, an innovative ECG interpretation and acute cardiac care course originally developed in the Quebec & Montreal 🫀 Institutes! Or go to https://t.co/89yxZ8XwnD for info and to register!
Read the 12 key points to remember about this scientific statement from the AHA for the management of patients at risk for and with left ventricular thrombus: https://t.co/CxoGBhuYNU #cvACS
Excited to be attending the 2022 Vulnerable Plaque, Vulnerable Patient Meeting, joining a terrific group of faculty to speak on advanced #plaque analysis using #yesCCT.
Virtual attendance is an option 👉 https://t.co/VnSjlseynR
I am a steering committee member of SOS-AMI, a phase 3 study that has the potential to change the paradigm of AMI treatment. Talk to me at #esccongress in Barcelona if you run into me! #iampartofsosami
19) So what have we learned?
Which of these effects, originally thought to help explain the #CV and #cardiorenal benefits of #SGLT2i, has data shown actually to be NOT so important?
a.⬆️urinary glucose excretion
b.⬆️urinary volume
c.⬆️natriuresis
d.⬇️renal vascular resistance